The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

WHO has officially recommended twice-yearly injectable lenacapavir for HIV prevention, marking a major shift in global HIV strategy with potential to curb new infections and improve access worldwide.

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

World Health Organization (WHO) recommends injectable lenacapavir for Human Immunodeficiency Virus (HIV) prevention ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

One way to cope with cuts in HIV prevention funding is to continue to push to increase the number of people who self-test for HIV instead of getting tested at a clinic or hospital, experts at a series ...